Rollover Study for Participants Who Have Completed a Previous Clinical Study With Anifrolumab (Saphnelo) and Clinically Benefited From Continued Treatment (ROSY-S)

November 9, 2026 updated by: AstraZeneca

ROSY-S: Rollover Study for Participants Who Have Completed a Previous Study With Anifrolumab (Saphnelo) and Are Assessed by the Investigator to Clinically Benefit From Continued Treatment

The purpose of this study is to provide continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment at the end of a parent clinical study, as assessed by the Investigator, while monitoring safety and tolerability.

Study details include:

  • Participants can transition in ROSY-S once they complete their participation in the parent study and should have received at least one dose of anifrolumab in the parent study. Participants with a treatment gap from parent studies and/or who are on compassionate use are eligible to rollover to ROSY-S study.
  • The earliest that the Enrolment Visit may occur is at the time of the last visit of the parent study (ie, completion of the parent study's final safety follow-up visit). All required assessments from the safety follow-up visit of the parent study must be completed before the Enrolment Visit of ROSY-S study.
  • The participants will continue to receive anifrolumab the same way they received it in the parent trial
  • A participant is considered to have completed the study when they meet one of the discontinuation criteria.
  • Safety will be monitored throughout the study. Both serious and nonserious AEs will be collected up to 12 weeks after the last dose of anifrolumab and will be reported as part of the primary safety endpoint.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

1072

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

      • Quilmes, Argentina, 1878
        • Not yet recruiting
        • Research Site
      • San Miguel, Argentina, 1663
        • Not yet recruiting
        • Research Site
      • Melbourne, Australia, 3004
        • Not yet recruiting
        • Research Site
      • Mitcham, Australia, 3132
        • Not yet recruiting
        • Research Site
      • Westmead, Australia, 2145
        • Not yet recruiting
        • Research Site
      • Graz, Austria, 8036
        • Not yet recruiting
        • Research Site
      • Graz, Austria, 8010
        • Not yet recruiting
        • Research Site
      • Linz, Austria, 4020
        • Not yet recruiting
        • Research Site
      • Vienna, Austria, 1130
        • Not yet recruiting
        • Research Site
      • Ghent, Belgium, 9000
        • Not yet recruiting
        • Research Site
      • Leuven, Belgium, 3000
        • Not yet recruiting
        • Research Site
      • Belo Horizonte, Brazil, 30150-221
        • Not yet recruiting
        • Research Site
      • Porto Alegre, Brazil, 90035-903
        • Not yet recruiting
        • Research Site
      • Rio de Janeiro, Brazil, 22470-220
        • Not yet recruiting
        • Research Site
      • Salvador, Brazil, 40150-150
        • Not yet recruiting
        • Research Site
      • São Paulo, Brazil, 05403-000
        • Not yet recruiting
        • Research Site
      • Haskovo, Bulgaria, 6304
        • Not yet recruiting
        • Research Site
      • Plovdiv, Bulgaria, 4001
        • Not yet recruiting
        • Research Site
      • Sofia, Bulgaria, 1618
        • Not yet recruiting
        • Research Site
      • Sofia, Bulgaria, 1463
        • Not yet recruiting
        • Research Site
      • Québec, Canada, G1V 3M7
        • Not yet recruiting
        • Research Site
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X5
        • Not yet recruiting
        • Research Site
      • Santiago, Chile, 7500571
        • Not yet recruiting
        • Research Site
      • Beijing, China, 100191
        • Not yet recruiting
        • Research Site
      • Chongqing, China, 400010
        • Not yet recruiting
        • Research Site
      • Guangzhou, China, 510080
        • Not yet recruiting
        • Research Site
      • Jinan, China, 250022
        • Not yet recruiting
        • Research Site
      • Lanzhou, China, 730000
        • Not yet recruiting
        • Research Site
      • Shanghai, China, 200001
        • Not yet recruiting
        • Research Site
      • Shenzhen, China, 518020
        • Not yet recruiting
        • Research Site
      • Shenzhen, China, 518053
        • Not yet recruiting
        • Research Site
      • Bogotá, Colombia, 110221
        • Not yet recruiting
        • Research Site
      • Prague, Czechia, 12850
        • Not yet recruiting
        • Research Site
      • Bordeaux, France, 33076
        • Not yet recruiting
        • Research Site
      • Nantes, France, 44093
        • Not yet recruiting
        • Research Site
      • Paris, France, 75014
        • Not yet recruiting
        • Research Site
      • Paris, France, 75020
        • Not yet recruiting
        • Research Site
      • Paris, France, 75010
        • Not yet recruiting
        • Research Site
      • Poitiers, France, 86000
        • Not yet recruiting
        • Research Site
      • Rennes, France, 35033
        • Not yet recruiting
        • Research Site
      • Strasbourg, France, 67200
        • Not yet recruiting
        • Research Site
      • Toulouse, France, 31059
        • Not yet recruiting
        • Research Site
      • Toulouse, France, 31300
        • Not yet recruiting
        • Research Site
      • Berlin, Germany, 13353
        • Not yet recruiting
        • Research Site
      • Dresden, Germany, 1309
        • Not yet recruiting
        • Research Site
      • Essen, Germany, 45122
        • Not yet recruiting
        • Research Site
      • Freiburg im Breisgau, Germany, 79106
        • Not yet recruiting
        • Research Site
      • Freiburg im Breisgau, Germany, 79104
        • Not yet recruiting
        • Research Site
      • Hanover, Germany, 30625
        • Not yet recruiting
        • Research Site
      • Kiel, Germany, 24105
        • Not yet recruiting
        • Research Site
      • Mainz, Germany, 55131
        • Not yet recruiting
        • Research Site
      • Marburg, Germany, 35043
        • Not yet recruiting
        • Research Site
      • Münster, Germany, 48149
        • Not yet recruiting
        • Research Site
      • Regensburg, Germany, 93053
        • Not yet recruiting
        • Research Site
      • Tübingen, Germany, 72076
        • Not yet recruiting
        • Research Site
      • Wuppertal, Germany, 42283
        • Not yet recruiting
        • Research Site
      • Chaïdári, Greece, 124 62
        • Not yet recruiting
        • Research Site
      • Hyderabad, India, 500082
        • Not yet recruiting
        • Research Site
      • Kolkata, India, 700020
        • Not yet recruiting
        • Research Site
      • New Delhi, India, 110060
        • Not yet recruiting
        • Research Site
      • Pune, India, 411001
        • Not yet recruiting
        • Research Site
      • Haifa, Israel, 31048
        • Not yet recruiting
        • Research Site
      • Kfar Saba, Israel, 4428164
        • Not yet recruiting
        • Research Site
      • Brescia, Italy, 25123
        • Not yet recruiting
        • Research Site
      • Catania, Italy, 95123
        • Not yet recruiting
        • Research Site
      • Cona, Italy, 44124
        • Not yet recruiting
        • Research Site
      • Florence, Italy, 50121
        • Not yet recruiting
        • Research Site
      • Milan, Italy, 20122
        • Not yet recruiting
        • Research Site
      • Milan, Italy, 20132
        • Not yet recruiting
        • Research Site
      • Naples, Italy, 80131
        • Not yet recruiting
        • Research Site
      • Pavia, Italy, 27100
        • Not yet recruiting
        • Research Site
      • Roma, Italy, 00168
        • Not yet recruiting
        • Research Site
      • Roma, Italy, 00144
        • Not yet recruiting
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Not yet recruiting
        • Research Site
      • Kanazawa, Japan, 920-8641
        • Not yet recruiting
        • Research Site
      • Maebashi, Japan, 371-8511
        • Not yet recruiting
        • Research Site
      • Nagoya, Japan, 467-8602
        • Not yet recruiting
        • Research Site
      • Sapporo, Japan, 060-8648
        • Not yet recruiting
        • Research Site
      • Yokohama, Japan, 236-0004
        • Not yet recruiting
        • Research Site
      • Guadalajara, Mexico, 44650
        • Not yet recruiting
        • Research Site
      • Guadalajara, Mexico, 44950
        • Not yet recruiting
        • Research Site
      • México, Mexico, 11850
        • Not yet recruiting
        • Research Site
      • San Luis Potosí City, Mexico, 78250
        • Not yet recruiting
        • Research Site
      • Veracruz, Mexico, 91900
        • Not yet recruiting
        • Research Site
      • Rotterdam, Netherlands, 3015 GD
        • Not yet recruiting
        • Research Site
      • Iloilo City, Philippines, 5000
        • Not yet recruiting
        • Research Site
      • Lipa City, Philippines, 4217
        • Not yet recruiting
        • Research Site
      • Manila, Philippines, 1000
        • Not yet recruiting
        • Research Site
      • Bydgoszcz, Poland, 85-168
        • Not yet recruiting
        • Research Site
      • Katowice, Poland, 40-600
        • Not yet recruiting
        • Research Site
      • Kielce, Poland, 25-316
        • Not yet recruiting
        • Research Site
      • Krakow, Poland, 30-105
        • Not yet recruiting
        • Research Site
      • Krakow, Poland, 30-040
        • Not yet recruiting
        • Research Site
      • Lodz, Poland, 90-549
        • Not yet recruiting
        • Research Site
      • Ossy, Poland, 40-027
        • Not yet recruiting
        • Research Site
      • Warsaw, Poland, 00-807
        • Not yet recruiting
        • Research Site
      • Braga, Portugal, 4710-367
        • Not yet recruiting
        • Research Site
      • Lisbon, Portugal, 1000-064
        • Not yet recruiting
        • Research Site
      • Porto, Portugal, 4099-001
        • Not yet recruiting
        • Research Site
      • Bucharest, Romania, 011172
        • Not yet recruiting
        • Research Site
      • Cluj-Napoca, Romania, 400006
        • Not yet recruiting
        • Research Site
      • Iași, Romania, 700661
        • Not yet recruiting
        • Research Site
      • Belgrade, Serbia, 1100
        • Not yet recruiting
        • Research Site
      • Kragujevac, Serbia, 34000
        • Not yet recruiting
        • Research Site
      • Košice, Slovakia, 4001
        • Not yet recruiting
        • Research Site
      • Piešťany, Slovakia, 92101
        • Not yet recruiting
        • Research Site
      • Johannesburg, South Africa, 2193
        • Not yet recruiting
        • Research Site
      • Seoul, South Korea, 03080
        • Not yet recruiting
        • Research Site
      • Seoul, South Korea, 06973
        • Not yet recruiting
        • Research Site
      • Seoul, South Korea, 04763
        • Not yet recruiting
        • Research Site
      • Seoul, South Korea, 04401
        • Not yet recruiting
        • Research Site
      • Seoul, South Korea, 6591
        • Not yet recruiting
        • Research Site
      • A Coruña, Spain, 15006
        • Not yet recruiting
        • Research Site
      • Barcelona, Spain, 08003
        • Not yet recruiting
        • Research Site
      • Barcelona, Spain, 8041
        • Not yet recruiting
        • Research Site
      • Barcelona, Spain, 8950
        • Not yet recruiting
        • Research Site
      • Castellon, Spain, 12004
        • Not yet recruiting
        • Research Site
      • Granada, Spain, 18014
        • Not yet recruiting
        • Research Site
      • Las Palmas de Gran Canaria, Spain, 35020
        • Not yet recruiting
        • Research Site
      • Madrid, Spain, 28040
        • Not yet recruiting
        • Research Site
      • Madrid, Spain, 28034
        • Not yet recruiting
        • Research Site
      • Madrid, Spain, 28041
        • Not yet recruiting
        • Research Site
      • Valencia, Spain, 46014
        • Not yet recruiting
        • Research Site
      • Valencia, Spain, 46017
        • Not yet recruiting
        • Research Site
      • Valladolid, Spain, 47012
        • Not yet recruiting
        • Research Site
      • Vigo, Spain, 36200
        • Not yet recruiting
        • Research Site
      • Kaohsiung City, Taiwan, 83301
        • Not yet recruiting
        • Research Site
      • Kaohsiung City, Taiwan, 813414
        • Not yet recruiting
        • Research Site
      • Taichung, Taiwan, 40705
        • Not yet recruiting
        • Research Site
      • Taichung, Taiwan, 404327
        • Not yet recruiting
        • Research Site
      • Taipei, Taiwan, 10449
        • Not yet recruiting
        • Research Site
      • Bangkok, Thailand, 10700
        • Not yet recruiting
        • Research Site
      • Bangkok, Thailand, 10330
        • Not yet recruiting
        • Research Site
      • Hat Yai, Thailand, 90110
        • Not yet recruiting
        • Research Site
      • Khon Kaen, Thailand, 40002
        • Not yet recruiting
        • Research Site
      • Klong Luang, Thailand, 12120
        • Not yet recruiting
        • Research Site
      • Fatih-Istanbul, Turkey (Türkiye), 34098
        • Not yet recruiting
        • Research Site
      • Ümraniye, Turkey (Türkiye), 34760
        • Not yet recruiting
        • Research Site
      • Cambridge, United Kingdom, CB2 2QQ
        • Not yet recruiting
        • Research Site
      • Leeds, United Kingdom, LS7 4SA
        • Not yet recruiting
        • Research Site
      • London, United Kingdom, SE5 9RS
        • Not yet recruiting
        • Research Site
      • London, United Kingdom, NW1 2BU
        • Not yet recruiting
        • Research Site
      • Newcastle upon Tyne, United Kingdom, NE7 7DN
        • Not yet recruiting
        • Research Site
      • Sheffield, United Kingdom, S10 2JF
        • Not yet recruiting
        • Research Site
    • Arizona
      • Phoenix, Arizona, United States, 85028
        • Not yet recruiting
        • Research Site
    • California
      • Irvine, California, United States, 92617
        • Not yet recruiting
        • Research Site
      • Los Angeles, California, United States, 90045
        • Recruiting
        • Research Site
      • San Francisco, California, United States, 94115
        • Not yet recruiting
        • Research Site
    • Florida
      • Boca Raton, Florida, United States, 33486
        • Recruiting
        • Research Site
      • Fort Lauderdale, Florida, United States, 33309
        • Recruiting
        • Research Site
    • Illinois
      • Chicago, Illinois, United States, 60611
        • Not yet recruiting
        • Research Site
    • Indiana
      • Indianapolis, Indiana, United States, 46202
        • Not yet recruiting
        • Research Site
    • Maryland
      • Baltimore, Maryland, United States, 21287
        • Not yet recruiting
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, United States, 02115
        • Not yet recruiting
        • Research Site
    • Michigan
      • Ann Arbor, Michigan, United States, 48109
        • Not yet recruiting
        • Research Site
    • Minnesota
      • Rochester, Minnesota, United States, 55905
        • Not yet recruiting
        • Research Site
    • Nebraska
      • Omaha, Nebraska, United States, 68114
        • Not yet recruiting
        • Research Site
    • New York
      • New York, New York, United States, 10029
        • Not yet recruiting
        • Research Site
    • North Carolina
      • Charlotte, North Carolina, United States, 28207
        • Recruiting
        • Research Site
    • Ohio
      • Cleveland, Ohio, United States, 44195
        • Not yet recruiting
        • Research Site
      • Columbus, Ohio, United States, 43230
        • Not yet recruiting
        • Research Site
    • Oregon
      • Portland, Oregon, United States, 97239
        • Not yet recruiting
        • Research Site
    • South Carolina
      • Charleston, South Carolina, United States, 29425
        • Not yet recruiting
        • Research Site
    • Texas
      • Dallas, Texas, United States, 75390-8843
        • Not yet recruiting
        • Research Site
    • Virginia
      • Roanoke, Virginia, United States, 24016
        • Not yet recruiting
        • Research Site
      • Hà Nội, Vietnam, 100000
        • Not yet recruiting
        • Research Site

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

5 years to 80 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants are eligible to be included in the study only if all of the following criteria apply:

    1 Participants must have completed the entirety of the parent study and should have received at least one dose of anifrolumab in the parent study.

  • In the opinion of the Investigator, the potential benefit to the participant of continuing anifrolumab at the end of the parent study outweighs the risk.

  • Contraceptive use by participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Participants should continue following the contraception requirements as per Appendix B from study enrolment up to 16 weeks after the last dose of study treatment.

  • Capable of giving signed informed consent described in Appendix A which includes compliance with the requirements and restrictions listed in the ICF and in this protocol.

  • Capable of adhering to the treatment plan related to this ROSY-S study.

Exclusion Criteria:

  • Participant develops hypersensitivity to any of the components of anifrolumab.
  • Female participant who is breastfeeding, pregnant, or intends to become pregnant during participation in this study.
  • Currently participating in any investigational study or participated in an investigational study within 30 days prior to enrolment or within 5 half-lives of the investigational medicinal product (other than the parent study for anifrolumab) whichever is longer.
  • Ongoing, unresolved AE requiring interruption of treatment at the end of the prior parent study (ie, when the parent study is either completed or closed) that in the Investigator's opinion would prevent restarting anifrolumab.
  • Currently receiving or have received prohibited medication(s) as specified in parent protocols prior to signing ICF.
  • Participants who are planning to use live/live-attenuated vaccines.
  • Participants who are planning to use any other therapies, including B-cell therapies, that in the opinion of the Investigator could jeopardize or would compromise the participant's ability to participate in the program as determined by the Investigator.
  • Participants with any medical condition (such as cancer or viral infections [hepatitis]) or psychiatric condition that, in the opinion of the Investigator, could jeopardise or would compromise the participant's ability to participate in this study as determined by the Investigator based on protocol required assessments.
  • Participants who discontinued the parent study prior to completion of all study visits.
  • Local access to approved and commercially available (reimbursed) drug for the defined indication as permitted by local/country regulation.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Non-Randomized
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Anifrolumab

This is a single arm open-label study with the primary objective of providing continued access to anifrolumab to eligible participants who are continuing to derive clinical benefit from treatment and assessing long-term safety and tolerability of anifrolumab until participant meets one of the study discontinuation criteria.

Anifrolumab pre-filled syringe

Anifrolumab solution for injection in pre-filled pen

Anifrolumab concentrate for solution for infusion

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
SAEs and Non-Serious AEs
Time Frame: From first dose administered and until 12 weeks after the last dose of Anifrolumab

Safety will be evaluated by monitoring and assessing SAEs and Non-Serious AEs as reported throughout the study and until 12 weeks after the last dose of anifrolumab

From first dose administered and until 12 weeks after the last dose of Anifrolumab

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

August 31, 2026

Primary Completion (Estimated)

December 30, 2032

Study Completion (Estimated)

December 30, 2032

Study Registration Dates

First Submitted

June 23, 2026

First Submitted That Met QC Criteria

July 7, 2026

First Posted (Actual)

July 9, 2026

Study Record Updates

Last Update Posted (Actual)

November 10, 2026

Last Update Submitted That Met QC Criteria

November 9, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • D346BC00004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment. "Yes" indicates that AstraZeneca is accepting requests for IPD, but this does not mean all requests will be shared.

IPD Sharing Time Frame

AstraZeneca will meet or exceed data availability commitments in line with EFPIA/PhRMA Data Sharing Principles. For details of timelines, refer to AstraZeneca's disclosure commitment.

IPD Sharing Access Criteria

When a request has been approved, AstraZeneca will provide access to anonymized individual patient-level data via a secure research environment (Vivli). A signed Data Usage Agreement must be in place before accessing the data.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.